Innovation for Future Health – Vinnova in Life Sciences

Gunnar Sandberg, PhD
Health Division, Vinnova
Vinnova in brief

• Swedish government agency working under the Ministry of Enterprise

• During 2015 the funds for Research and Development was 2.6 billion SEK.

• National responsibility for providing information and advice regarding the EU’s Framework Programme for Research and Technical Development

• Over 200 people work at Vinnova’s offices in Stockholm and Brussels

• Our Director General is Charlotte Brogren
Three roles

Funding Research & Innovation

National EU Contact Agency

Expert Agency
2.6 billion kronor invested by Vinnova in Swedish research and innovation in 2015.

- Universities
- Private companies
- Research institutes
- Public administration
- Miscellaneous
Health and Life Science at Vinnova 2016 Challenges

- Ageing population
- Increase in chronic and lifestyle diseases
- Antimicrobial resistance
- Non-compatible IT-systems
Projects with relevance for health and life science

Antal projekt

1922
80%

490
20%

Total finansiering, SEK

6 577 94 488

14 846 63 044

Projekt med relevans för hälsa
Övriga projekt
Meeting health challenges through innovation

- Efficiency and quality-driven health-care and social care
- Competitive and innovative business sector
- Collaborative ecosystem
20 testbeds and innovation hubs

Innovation management

The digital paradigm shift

Reimbursement models
Swedish Testbed for Innovative Radiotherapy

A combined magnetic resonance scanner and radiotherapy treatment unit at Uppsala Hospital. This will be one of the first installations in the world of this next generation radiotherapy treatment unit, developed by Elekta, Siemens, ScandiDos, Cureos, Micorpos Medical, Gold Anchos.
AstraZeneca BioVentureHub - a novel Public-Private-Partnership model

• Established in 2014 with the aim to stimulate competitiveness in the life science industry

• Currently 17 small companies and 1 academic group

• Emerging life science companies and academic groups on AstraZeneca Gothenburg R&D site

• Rental agreement with full independence

• Open doors

• Possibilities to access AstraZeneca skills and infrastructure

• No strings attached – cost neutral to AstraZeneca via external funds

www.azbioventurehub.com
A catalyst for life science innovation

"AstraZeneca’s BioVentureHub is an exciting innovation model for strengthening competitiveness and collaboration in the life science industry. It’s smart Swedish industry in action, serving as inspiration to other companies and industries when it comes to generating opportunities in the new industry era."

Mikael Damberg
Swedish Minister for Enterprise and Innovation
Spin-Out – a pioneering model for collaborative innovation

Background – As part of its innovation partnership program, the Swedish government wants to see more life science companies in Sweden.

AstraZeneca and Vinnova are collaborating to develop a new innovation model to make it possible to breathe life into projects and innovations that established companies, for various reasons, have decided not to commercialize.

How? – By recycling non-commercialized innovations, that have value, in the form of new companies.
Innovative SMEs

Programme innovation projects in companies finance the development of business concepts with great international potential of applying new knowledge or new technology. Projects must be in an early phase of development where commercial and development risks remain. The aim is for companies to attract resources to complete the development of the business concept.

www.vinnova.se/smf
Eurostars

For SMEs with their own research and supports market-oriented R & D projects with partners from at least two countries

www.vinnova.se/smf
Next-generation biologics
"to take the lead in research and production of biopharmaceuticals"
A billion SEK investment

- Swedish government and participating companies
  400 MSEK
- Knut and Alice Wallenberg foundation, universities
  and AstraZeneca 510 MSEK
Challengedriven innovation:

• VINNOVA has identified four societal challenges where Sweden is considered to have good potential for international leading innovation of which is the Future Health Care.

Challenges for the Future Health Care
The good health of the population and a functioning health care for all are key requirements for sustainable growth.

www.vinnova.se/udi
Digipat – Optimized workflows and IT tools for digital pathology

- Increased patient safety through faster and high-quality diagnosis
- IT tools for digital pathology that can provide groundbreaking improvements with respect to efficiency and quality of care
- Counties, hospitals, laboratories, medtech companies, universities and research institutes
Renewal

Joint vision and objectives

Stakeholder driven

Open to all

Inter-disciplinary

Long term investment

Research and innovation

Renewal

STRATEGISKA INNOVATIONSPROGRAM
100 MSEK per year building future health innovation
National Innovation Program for a competitive life science ecosystem in Sweden

Goal: National use of expertise and resources

Evidence- and value-based healthcare and personalised medicine in practice

Swedish healthcare has introduced and established more value-creating innovations

Life Science in Sweden is internationally competitive

Increasing research and development in Life Science in Sweden.

www.swelife.se
Medtech4Health

National innovation program that supports medical innovation in Sweden.
Goal: Contribute to improvements for patients and health care at the same time lead to industrial growth and increased exports.
medtech4health.se
Think differently